Stemline Therapeutics, Inc. - Product Pipeline Review - 2016

Published: Aug, 2016 | Pages: 49 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Stemline Therapeutics, Inc. - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'Stemline Therapeutics, Inc. - Product Pipeline Review - 2016', provides an overview of the Stemline Therapeutics, Inc.'s pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Stemline Therapeutics, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Stemline Therapeutics, Inc.
- The report provides overview of Stemline Therapeutics, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Stemline Therapeutics, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Stemline Therapeutics, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate Stemline Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Stemline Therapeutics, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Stemline Therapeutics, Inc.'s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Stemline Therapeutics, Inc. Snapshot 6
Stemline Therapeutics, Inc. Overview 6
Key Information 6
Key Facts 6
Stemline Therapeutics, Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
Stemline Therapeutics, Inc. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Stemline Therapeutics, Inc. - Pipeline Products Glance 12
Stemline Therapeutics, Inc. - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
Stemline Therapeutics, Inc. - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Stemline Therapeutics, Inc. - Drug Profiles 15
SL-401 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
SL-701 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
SL-801 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Monoclonal Antibodies to Inhibit IL-3RA for Autoimmune Disorders 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Monoclonal Antibody to Antagonize Frizzled Receptor for Oncology 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Monoclonal Antibody to Antagonize Patched for Oncology 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Monoclonal Antibody to Antagonize Tie-1 Receptor for Oncology 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Monoclonal Antibody to Inhibit CD133 for Oncology 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Monoclonal Antibody to Inhibit Glypican-3 for Oncology 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Monoclonal Antibody to Inhibit Smoothened for Oncology 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
SL-101 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
SL-201 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
SL-202 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
SL-301 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
SL-302 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
SL-501 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
SL-601 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Stemline Therapeutics, Inc. - Pipeline Analysis 36
Stemline Therapeutics, Inc. - Pipeline Products by Target 36
Stemline Therapeutics, Inc. - Pipeline Products by Route of Administration 37
Stemline Therapeutics, Inc. - Pipeline Products by Molecule Type 38
Stemline Therapeutics, Inc. - Pipeline Products by Mechanism of Action 39
Stemline Therapeutics, Inc. - Recent Pipeline Updates 40
Stemline Therapeutics, Inc. - Dormant Projects 46
Stemline Therapeutics, Inc. - Locations And Subsidiaries 47
Head Office 47
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 48
Disclaimer 49

List of Tables

Stemline Therapeutics, Inc., Key Information 6
Stemline Therapeutics, Inc., Key Facts 6
Stemline Therapeutics, Inc. - Pipeline by Indication, 2016 8
Stemline Therapeutics, Inc. - Pipeline by Stage of Development, 2016 10
Stemline Therapeutics, Inc. - Monotherapy Products in Pipeline, 2016 11
Stemline Therapeutics, Inc. - Phase II, 2016 12
Stemline Therapeutics, Inc. - Phase I, 2016 13
Stemline Therapeutics, Inc. - Preclinical, 2016 14
Stemline Therapeutics, Inc. - Pipeline by Target, 2016 36
Stemline Therapeutics, Inc. - Pipeline by Route of Administration, 2016 37
Stemline Therapeutics, Inc. - Pipeline by Molecule Type, 2016 38
Stemline Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2016 39
Stemline Therapeutics, Inc. - Recent Pipeline Updates, 2016 40
Stemline Therapeutics, Inc. - Dormant Developmental Projects,2016 46